Lung cancer is the leading cause of cancer-related death worldwide, ranking first among men and second among women for both incidence and mortality. Surgery remains the primary treatment for early-stage, resectable non-small cell lung cancer (NSCLC), encompassing stages I and selected cases of stage IIIB. For patients with stage II to III disease, as well as some stage IB tumors, neoadjuvant or adjuvant systemic therapies are recommended. It is well recognized that specific driver gene mutations play a critical role in tumor progression and aggressiveness, and patients with these genetic alterations may benefit from targeted treatment approaches. These alterations are referred to as “druggable”, “targetable”, or “actionable”, representing specific targets for personalized treatments. Tyrosine kinase inhibitors (TKIs) are now the preferred first-line treatment for patients harboring mutations in EGFR, ALK, ROS1, and BRAF. Additionally, targeted therapies exist for patients with alterations in RET, ERBB2, KRAS, MET, and NTRK, either for those who have received prior treatments or as part of ongoing clinical trials. The success of targeted therapies is reshaping treatment approaches for NSCLC with targetable driver gene alterations, both in early-stage and locally advanced settings. This review focuses on current therapeutic strategies that combine targeted therapies with surgical resection in patients with resectable non-small cell lung cancer (NSCLC) harboring actionable driver gene alterations.
肺癌是全球癌症相关死亡的首要原因，其发病率和死亡率在男性中居首位，在女性中居第二位。手术仍是早期可切除非小细胞肺癌（涵盖Ⅰ期及部分ⅢB期病例）的主要治疗手段。对于Ⅱ期至Ⅲ期患者以及部分ⅠB期肿瘤，推荐采用新辅助或辅助全身治疗。学界公认特定驱动基因突变在肿瘤进展和侵袭性中起关键作用，携带这些基因改变的患者可能从靶向治疗中获益。这些基因改变被称为"可药物化"、"可靶向"或"可干预"改变，代表着个体化治疗的特异性靶点。目前，酪氨酸激酶抑制剂已成为携带EGFR、ALK、ROS1和BRAF突变患者的一线优选治疗方案。此外，针对RET、ERBB2、KRAS、MET和NTRK基因改变的患者，无论是既往接受过治疗者还是正在参与临床试验者，均有相应的靶向疗法可供选择。靶向治疗的成功正在重塑具有可靶向驱动基因改变的非小细胞肺癌（包括早期和局部晚期）的治疗模式。本综述重点探讨当前针对携带可干预驱动基因改变的可切除非小细胞肺癌患者，将靶向治疗与手术切除相结合的治疗策略。
肿瘤(癌症)患者之家